Skip to main content
. 2020 Jul 31;30:34. doi: 10.1038/s41533-020-00191-y

Table 2.

Baseline characteristics of people who continue and stop inhaled corticosteroids.

Non-stoppers Stoppers
N (%) N (%)
Denominator 708 219
Age at baseline (SD) 68.2 (11.8) 69.1 (12)
 <60 years 169 (23.9) 47 (21.5)
 ≥60 years 539 (76.1) 172 (78.5)
Gender
 Male 422 (59.6) 141 (64.4)
 Female 286 (40.4) 78 (35.6)
Ethnic Group
 White 513 (72.5) 142 (64.8)
 South Asian 148 (20.9) 62 (28.3)
 Black 18 (2.5) 7 (3.2)
 Other/unknown 29 (4.1) 8 (3.7)
Deprivation quintile
 1 (least deprived) 142 (20.1) 44 (20.2)
 2 142 (20.1) 44 (20.2)
 3 136 (19.2) 47 (21.6)
 4 151 (21.4) 41 (18.8)
 5 (most deprived) 136 (19.2) 42 (19.3)
Smoking Status
 Current non-smoker 405 (57.7) 140 (64.2)
 Current smoker 297 (42.3) 78 (35.8)
Baseline comorbidities
 Atrial fibrillation 50 (7.1) 24 (11)
 Cancer 70 (9.9) 22 (10)
 CHD 146 (20.6) 54 (24.7)
 CKD 131 (18.5) 44 (20.1)
 Dementia 16 (2.3) 6 (2.7)
 Depression 192 (27.1) 54 (24.7)
 Diabetes 182 (25.7) 64 (29.2)
 Epilepsy 13 (1.8) 4 (1.8)
 Heart failure 42 (5.9) 25 (11.4)
 Hypertension 341 (48.2) 106 (48.4)
 Osteoporosis 46 (6.5) 12 (5.5)
 Peripheral arterial disease 46 (6.5) 6 (2.7)
 Rheumatoid arthritis 18 (2.5) 9 (4.1)
 Serious mental illness 21 (3) 9 (4.1)
 Stroke 48 (6.8) 16 (7.3)

aBaseline is date of first ICS prescription during post-intervention period.